Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

International projects source: SICRIS

PERsonalized MEdicine Approach for Asthma and Allergy Biologicals SeLEction

Edit
Research activity

Code Science Field Subfield
3.01.00  Medical sciences  Microbiology and immunology   

Code Science Field
B001  Biomedical sciences  General biomedical sciences 
Keywords
asthma, allergy, children and young adults
Researchers (6)
no. Code Name and surname Research area Role Period No. of publications
1.  33666  PhD Vojko Berce  Microbiology and immunology  Researcher  2019 - 2023  227 
2.  29835  PhD Tomaž Budefeld  Microbiology and immunology  Researcher  2020 - 2023  92 
3.  26010  PhD Boris Gole  Biochemistry and molecular biology  Researcher  2019 - 2023  74 
4.  33268  PhD Mario Gorenjak  Biochemistry and molecular biology  Researcher  2019 - 2023  164 
5.  16340  PhD Uroš Potočnik  Microbiology and immunology  Researcher  2019 - 2023  630 
6.  28417  PhD Katja Repnik  Microbiology and immunology  Researcher  2019  132 
Organisations (1)
no. Code Research organisation City Registration number No. of publications
1.  2334  University of Maribor, Faculty of Medicine  Maribor  5089638048  16,534 
Abstract
In total, 50 million Europeans are affected by allergic diseases such as asthma and atopic dermatitis. Approximately 10% of patients with asthma and atopic dermatitis suffer from uncontrolled disease despite high doses of steroids. These patients can benefit from innovative targeted, but also expensive and burdensome treatments, so-called biologicals. A transparent access to biologicals and a systematic assessment of treatment response is missing, causing distress to patients and a burden to public health. Aim of the multi-disciplinary PERMEABLE consortium is to develop the urgently needed personalized medicine approach for a just, save and effective, thus PERMEABLE access to biologicals for allergy patients across Europe, based on individual susceptibility to molecular mechanisms targeted by the available biologicals. This study combines (a) clinical research to define and structure clinical decision-making and to apply these in a proof-of-principle Pan-European cohort of young biologicals users with (b) advanced preclinical studies using innovative functional cell models and non-invasive omics to develop clinical applications, and (c) scalable, cloud-based IT solutions to allow for multilingual data management, big data analysis and clinical-decision making tools to guide treatment.
Confirmation required
Views history
Favourite